Visual acuity improved beyond that expected in relation to reduction in central macular thickness when a 2.5 mg dose of intravitreal ziv-aflibercept was used in patients with diabetic macular edema, according to a study.
CMT and BCVA were evaluated over the course of 1 year of treatment with 2.5 mg or 1.25 mg of intravitreal ziv-aflibercept (IVZ; Zaltrap, Regeneron) compared with 1.25 mg bevacizumab (IVB; Avastin, Genentech) in eyes with DME.
The study included 42 eyes in the 2.5 mg IVZ cohort, 42 eyes in the 1.25 mg IVZ cohort and 39 eyes in the IVB cohort, which respectively received 6.71,
Uncategorized